GGrantIndex
Sort

85,873 grants matching alzheimers

Discovery and optimization of ApoE4 correctors for the treatment of Alzheimer's Disease

$877,636
Michael Jackson · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · AG

Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA)

$877,584
Hector M Gonzalez · University Of California, San Diego · R01 · FY2018 · AG

Neural mechanisms of gait disturbances as individualized digital biomarker trajectories in preclinical dementia

$877,523
Ehsan Adeli · Stanford University · R01 · FY2025 · AG

Epigenome Interactions in Complex Neurogenetic Disorders

$877,497
Margaret Elizabeth Ross · Weill Medical Coll Of Cornell Univ · R01 · FY2015 · NS

Regulation mechanism and functional genomics of LINE1 RNA in TDP-43 linked neurodegeneration

$877,436
Shuying Sun · Johns Hopkins University · R01 · FY2022 · AG

Core C- Biostatistics and Data Analysis Core

$877,373
Adam Christian Naj · University Of Pennsylvania · U54 · FY2025 · AG

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

$877,287
Mark W Albers · Massachusetts General Hospital · U01 · FY2021 · DC

Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease

$877,246
Scott Allen Noggle · New York Stem Cell Foundation · R01 · FY2019 · AG

Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease

$877,246
Scott Allen Noggle · New York Stem Cell Foundation · R01 · FY2021 · AG

Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease

$877,246
Valentina Fossati · New York Stem Cell Foundation · R01 · FY2022 · AG

Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease

$877,246
Scott Allen Noggle · New York Stem Cell Foundation · R01 · FY2020 · AG

Compound repositioning for Alzheimer's Disease using knowledge graphs, insurance claims data, and gene expression complementarity

$877,205
Andrew I Su · Scripps Research Institute, The · R01 · FY2024 · AG

Core B - Clinical Core

$877,116
David A Wolk · University Of Pennsylvania · P30 · FY2020 · AG

PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer Research

$877,112
Catherine M. Tangen · Fred Hutchinson Cancer Center · U01 · FY2022 · CA

Training in the Molecular Biology of Neurodegeneration and Alzheimer's Disease

$877,047
Bruce A Yankner · Harvard Medical School · T32 · FY2020 · AG

Lipids in Brain Disease and Neuroinflammation: Animal Models

$876,974
Stanley I Rapoport · National Institute On Aging · ZIA · FY2012 · AG

Research Program on Cognition and Neuromodulation Based Interventions (RP-CNBI)

$876,688
Benjamin Michael Hampstead · University Of Michigan At Ann Arbor · R35 · FY2022 · AG

Molecular & Behavioral Effects of Low Level Mn Exposure

$876,163
Tomas R Guilarte · Columbia University Health Sciences · R01 · FY2011 · ES

Pro-Electrophilic Drugs PEDs for Alzheimer's Disease

$876,156
Stuart A Lipton · Scripps Research Institute, The · R56 · FY2021 · AG

ALZHEIMERS DISEASE CORE CENTER

$875,958
Northwestern University · P30 · FY2000 · AG

Cell autonomous and non-cell autonomous roles of the GWAS risk factor BIN1 in Alzheimer's disease neuropathology

$875,883
Gopal Thinakaran · University Of South Florida · RF1 · FY2016 · AG

ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease

$875,721
Yadong Huang · J. David Gladstone Institutes · R01 · FY2017 · AG

Mechanisms of Somatic Mutation in Alzheimer's Disease Using Single Neuron Analysis

$875,677
Michael B Miller · Brigham And Women'S Hospital · R01 · FY2025 · AG

Cellular Cofactors, Neuronal Stress & Rescue, Aging & Alzheimer Disease

$875,545
Shi Du Yan · University Of Kansas Lawrence · P01 · FY2010 · AG

VITAMIN E TRIAL IN PERSONS WITH DOWN SYNDROME

$875,473
Arthur Dalton · Institute For Basic Res In Dev Disabil · R01 · FY2009 · AG